The Cord Blood Banking Industry: Market Trends and Clinical Utility

The global cord blood banking market is projected to reach approximately $3.8 billion by 2028, according to data from Grand View Research. This growth is driven by increasing awareness of the therapeutic potential of hematopoietic stem cells, which are collected from umbilical cord blood at birth and stored for potential future medical use in treating blood disorders, immune deficiencies, and certain cancers.

What Is Cord Blood Banking?

Cord blood banking involves the collection and storage of blood remaining in the umbilical cord and placenta after a baby is born. This blood is a rich source of hematopoietic stem cells—the precursor cells that develop into red blood cells, white blood cells, and platelets.

According to the Mayo Clinic, these cells are currently used to treat over 80 diseases, including leukemia, lymphoma, and sickle cell anemia. Parents typically choose between two primary banking options:

• Public Cord Blood Banks: These facilities store donated cord blood for public use. If a match is found, the unit is provided to a patient in need, often at no cost to the donor family.
• Private Cord Blood Banks: Families pay an initial collection fee and annual storage fees to keep the cord blood for their own private use.

Why Is the Market Expanding?

The expansion of the cord blood industry is largely attributed to advancements in regenerative medicine and a growing pipeline of clinical trials. Research published in the Journal of Translational Medicine highlights that beyond traditional blood disorders, stem cells are being investigated for their role in treating neurological conditions, such as cerebral palsy, and autoimmune diseases.

Market analysts note that the rising prevalence of chronic diseases and the increasing number of successful transplants worldwide are encouraging healthcare providers to advocate for cord blood preservation. Additionally, the Health Resources and Services Administration (HRSA) maintains the National Cord Blood Inventory (NCBI) to ensure a diverse supply of high-quality cord blood units are available for patients who do not have a matched sibling donor.

Comparison of Banking Models

| Feature | Public Banks | Private Banks |
| :— | :— | :— |
| Primary Goal | Altruistic donation | Family security |
| Cost | Generally free | High initial and annual fees |
| Accessibility | Available to the public/registries | Reserved exclusively for the family |
| Availability | Subject to donation criteria | Guaranteed storage |

What Should Parents Consider?

The American College of Obstetricians and Gynecologists (ACOG) advises that families should carefully weigh the costs and benefits of private banking. ACOG notes that the likelihood of a child needing their own stored cord blood is relatively low. However, for families with a known history of genetic conditions that might be treatable with stem cells, private banking is often viewed as a form of biological insurance.

Before selecting a private bank, the Parent’s Guide to Cord Blood Foundation recommends verifying that the facility is accredited by the AABB (formerly the American Association of Blood Banks) or the Foundation for the Accreditation of Cellular Therapy (FACT). These accreditations ensure the facility meets rigorous standards for the processing, testing, and storage of biological products.

Future Outlook

The cord blood industry continues to evolve as researchers explore the use of “expanded” cord blood units—a process that increases the number of stem cells available in a single unit. This development addresses one of the primary limitations of cord blood: the relatively low volume of cells compared to bone marrow transplants. As clinical protocols improve and the success rates of transplants increase, cord blood remains a significant component of modern hematological care.